Recent News

ESMO 2025
IO102-IO103 cancer vaccine plus pembrolizumab for first line advanced melanoma: primary results from a randomized phase 3 trial (IOB-013/KN-D18)
ESMO 2025
IO102-IO103 cancer vaccine plus pembrolizumab for first line (1L) treatment of advanced solid tumors: final results of a phase 2 basket trial
AACR 2025
A TGFβ-directed immune-modulatory vaccine induces T cell activation and drives antitumor activity by modulating the tumor microenvironment
AACR 2025
Immune modulatory therapeutic cancer vaccines against IDO1 and PD-L1 control tumor growth through target specific changes in the tumor microenvironment
ESMO 2024
IOB-022/KN-D38 Clinical Trial: SCCHN Cohort
Dr. Jonathan Riess, Professor of Medicine at UC Davis Comprehensive Cancer Center
SITC 2024
Phase 2 trial of the IO1O2-IO103 cancer vaccine plus pembrolizumab
Results from the first-line cohort of PD-L1 high metastatic non-small cell lung cancer
Dr. Jonathan Riess, Professor of Medicine at UC Davis Comprehensive Cancer Center